On January 4, 2022 Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, reported that John P. Butler, Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 4:30 p.m. ET (Press release, Akebia, JAN 4, 2022, View Source [SID1234598143]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio replay of the presentation will be available through the Investors section of Akebia’s website at View Source for approximately 30 days following the conference.

On January 4, 2022 Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 2:15 p.m. EST (Press release, Protagonist, JAN 4, 2022, View Source [SID1234598140]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Patel will also participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference taking place virtually during January 10-13, 2022.

A live and archived webcast of the events will be available in the Investors section of the Protagonist Therapeutics website at View Source The fireside chat at H.C. Wainwright BioConnect will be available on January 10, 2022.

On January 4, 2022 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, reported that it will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference (Press release, Novavax, JAN 4, 2022, View Source [SID1234598138]). Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Presentation and Q&A

Date:

Monday, January 10, 2022

Time:

9:00 – 9:40 a.m. Eastern Time (ET)

Moderator:

Eric Joseph

Novavax participants:

Stanley C. Erck, President and Chief Executive Officer

Conference

Event:

Investor meetings

Date:

Monday, January 10, 2022 – Wednesday, January 12, 2022

An audio replay of the recorded presentation and Q&A will be available through the events page of the Company’s website at ir.novavax.com for 30 days.

On January 4, 2022 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022 (Press release, Mirati, JAN 4, 2022, View Source [SID1234598136]). David Meek, chief executive officer, will make a formal presentation and answer questions about the Company at 2:15 p.m. P.T. / 5:15 p.m. E.T.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com. A replay of the webcast will be made available following the event.

On January 4, 2022 PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, reported it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group (Press release, PRISM Pharma, JAN 4, 2022, View Source [SID1234598134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon identification of hit compounds, Roche and Genentech may elect to further develop and commercialize the compounds.

PRISM BioLab is eligible to receive an upfront payment, success-based milestone payments and royalties on future net sales. Specific financial terms are not disclosed.